NRx Pharmaceuticals, Inc. (NRXP) NASDAQ
4.12
-0.5(-10.82%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
NRx Pharmaceuticals, Inc.
Address
1201 Orange Street
Wilmington, DE 19801
United States of America (the)
Phone
484 254 6134
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
December 04, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Jonathan C. Javitt | Co-Founder, Chairman & CEO | 846,774 | 1957 |
| Dennis K. McBride | Chief Strategy Officer & Director | 38,462 | 1955 |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | 240,000 | 1962 |
| Michael S. Abrams | CFO & Treasurer | 363,083 | 1970 |
| Hervé Perron | Chief Scientist | 0 | 1959 |
| Philip T. Lavin | Chief Methodologist | 0 | 1947 |
| Glenn Tyson | Chief Commercial Officer | 0 | N/A |
| Joseph Casper | Chief Operating Officer | 0 | 1951 |
| Joshua C. Brown | Chief Medical Innovation Officer | 0 | N/A |
| Suzanne Messere | Investor Relations | 0 | N/A |
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
